peppersite
Metabolic supportsubcutaneous

AOD-9604

AOD-9604 is a lab-made chain of 16 amino acids copied from the tail end of human growth hormone, sold under the names HGH Fragment 176-191 and hexadecapeptide 177-191. It was studied for fat metabolism in animals and in six human trials of roughly 900 people, and the largest trial missed its main goal.

Researched for
Metabolic HealthBody CompositionRecovery

At a glance

Type
Metabolic support
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
300 mcg per Peptide Dosing Protocols. All 4 sources
Typical vial
5 mg in 3 mL

How much to draw

Full calculator →
Your draw
18units
0.18 mL on a U-100 insulin syringe
1.67 mg/mL16 doses per vial
Amount per dose

Opened on 300 mcg, the figure Peptide Dosing Protocols reports for AOD-9604, and a 5 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for AOD-9604 or for anything else, and nothing below has been checked against the study it came from.

250-300 mcg
Frequency
Once daily8-12 weeks
Route
subcutaneous or oral
Reported by
Peptide Protocol Wiki
Standard: 300-500 mcg/day · Low: 300 mcg · High: 500 mcg
Frequency
daily12-24 weeks · Cycle context Phase 2 protocols ran 12-24 weeks.
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysCommon research dose is 300-500 mcg/day.
300 mcg SC daily (commonly AM, fasted)
Frequency
once daily8-12 weeks · 8-12 week cycles
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
Referenced at 250-500 mcg once daily, up to 500 mcg-1 mg for aggressive fat loss protocols. Fasted morning administration cited. Noticeable results reported within 4-6 weeks.
Frequency
Once daily · Morning, fasted, before eating12 weeks on followed by a short break to prevent desensitization
Route
subcutaneous
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Bacteriostatic water
  • 3.0 mL bacteriostatic water for a 5 mg vial
  • Commonly 2 mg or 5 mg vials · Reconstitute with bacteriostatic water
Not yet audited

We have not published an audit on AOD-9604. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

AOD-9604 was made to test whether the fat-metabolism part of growth hormone could work without the full hormone's effects on muscle, blood sugar and IGF-1. In obese rats and mice it reduced weight gain. Researchers link the effect in mice to the beta-3 adrenergic receptor, but the source states that the mechanism of action is still unknown. In people, the 24-week Phase 2b trial did not meet its primary endpoint, and development for obesity was ended in February 2007.

In technical termsLipolytic and repair-related signaling.

Reported side effects

Seen in studies: six controlled trials in about 900 participants reported headache, fatigue, dizziness, cold-like symptoms (nasopharyngitis), diarrhea, flatulence, increased appetite, nausea and back pain, mostly mild or moderate. One case of severe chest tightness in the 50 mcg/kg IV group was judged possibly related to the drug. A small number of cancers were reported in the 12-week oral trial, and investigators considered them unrelated. In animal studies, rats showed changes in a bone-turnover marker, and high-dose female monkeys showed minimal-to-slight changes in liver cells.

Not ruled out: effects of injecting it under the skin, or of using it through the skin or nose, because no human exposure data has been published for those routes. The FDA's 2024 review raised immune reactions from peptide clumping and impurities as a concern for injectable routes. It also found that supplier certificates of analysis did not consistently control for impurities, aggregates or microbial limits. There is no long-term safety data beyond 24 weeks.

Who should avoid it

People who are pregnant, trying to become pregnant or breastfeeding: no published exposure data exists for these groups.

Anyone under 18: no published exposure data exists.

People with active or recent cancer: a small number of cancers were reported in the 12-week oral trial. Investigators considered them unrelated, but no long-term cancer safety data exists.

People with significant liver disease: a 9-month monkey study showed liver-cell changes that the FDA flagged as a possible safety signal.

People with poorly controlled bone-turnover conditions: a 26-week rat study showed dose-dependent changes in osteocalcin, a bone-turnover marker, that are not yet fully understood in humans.

Athletes in tested sport: it is on the World Anti-Doping Agency Prohibited List under category S2.2, and metabolites can be detected in urine.

People on prescription medicines: no drug-interaction studies have been published. In theory, medicines that affect glucose, lipid metabolism, growth hormone signaling or beta-adrenergic activity could interact.

What gets monitored

Weight, waist circumference, body composition, fasting glucose, basic lipid panel, IGF-1 at baseline and periodically, liver enzymes if there are preexisting liver concerns, and injection-site inspection. (reported by Peptide Dosing Protocols)

Common questions

What is AOD-9604?

AOD-9604 is a lab-made peptide of 16 amino acids. It matches the last 15 amino acids of human growth hormone, with an extra tyrosine added at one end to stabilize it. It was studied to see whether the fat-metabolism part of the hormone could work on its own.

Is AOD-9604 the same as HGH Fragment 176-191?

Yes, the names refer to the same end region of growth hormone. The source also lists hexadecapeptide 177-191 as another name.

Is AOD-9604 FDA-approved?

No. AOD-9604 is not FDA-approved for any therapeutic use. All material in circulation comes from research-supply or compounding sources.

What dose did the trials use?

The trials used oral doses from 0.25 mg to 30 mg per day and intravenous doses of 25 to 400 mcg/kg. The source notes that 1 mg/day did not show meaningfully better outcomes than lower doses.

Does AOD-9604 raise IGF-1 or blood sugar?

The source reports no statistically significant changes in IGF-1 or fasting glucose. The compound was designed to test fat metabolism without the blood-sugar and IGF-1 effects of full growth hormone.

Did AOD-9604 work for weight loss in humans?

Not in the largest trial. The 24-week Phase 2b trial of 502 adults with obesity did not meet its primary endpoint, and development for obesity was ended in February 2007. An earlier 12-week trial reported small statistically significant differences at the 1 mg dose, but that data has not been published in full peer-reviewed form.

How is AOD-9604 typically reconstituted in research-context use?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

What are the most commonly reported side effects?

Across the human trials, reported events included headache, fatigue, dizziness, diarrhea, flatulence and nausea. Most were mild or moderate.

Sources

  1. 01Mathew B, Amaechi C, Asante K, et al. FDA Evaluation of AOD-9604-Related Bulk Drug Substances. U.S. Food and Drug Administration (2024)
  2. 02Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism (2013)
  3. 03Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology (2001)
  4. 04Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research (2000)
  5. 05Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science (2015)
  6. 06Wilding JP. Treatment strategies for obesity (review including AOD-9604 clinical development). Obesity Reviews (2004)
  7. 07Cox HD, Lopes F, Woldemariam GA, et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations. Clinical Chemistry (2014)
  8. 08World Anti-Doping Agency. Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. World Anti-Doping Agency (2026)
  9. 09Metabolic Pharmaceuticals Limited. OPTIONS Study Phase 2b results announcement. Australian Stock Exchange filing (2007)
  10. 10More VG, Kenley DC. Safety evaluation of AOD9604, a synthetic peptide for use in obesity. International Journal of Toxicology (2014)
  11. 11DrugBank. AOD9604 drug summary. DrugBank Online (2026)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Sermorelin Acetate

Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.

Tesamorelin / Ipamorelin

This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.

Glutathione

Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.

MOTS-c

MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.

Tirzepatide

Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.